Abstract 2078P
Background
Chemotherapy-induced nausea and vomiting (CINV) occurs in two arbitrarily defined phases: the acute phase (from 0 to 24 h following chemotherapy (CT) initiation) and the delayed phase (from 24 to 120 h). Almost all antiemetic studies have therefore evaluated efficacy to 120 h after the administration of CT, and the period beyond 120 h is generally perceived to be relatively free of CINV, with some studies reporting continued nausea beyond the delayed phase.
Methods
In July and September of 2022, healthcare providers (HCPs) in Japan were recruited to complete an online quantitative survey. All HCPs were required to work with patients receiving anticancer CT in the hospital setting and have experience selecting, preparing and/or administering antiemetics. As part of this survey responses were collected on whether HCPs had patients who experienced nausea/vomiting (CINV) during Days 5-7 (beyond the delayed phase) after initiation of CT. Responses were also captured by CT regimen; for the physician subset, respondents were grouped by and analyzed only if they were prescribers of the chemotherapy type.
Results
A total of 809 HCPs (174 pharmacists, 102 nurses and 533 physicians) completed the survey. The physician group was comprised of breast surgeons (n = 57), pulmonologists (n = 107), gastroenterologists (n = 74), GI surgeons (89), gynecologists (n = 98), ENTs (n = 54), and oncologists (n = 54). The vast majority of respondents (98%, 93%, and 88% of pharmacists, nurses, and physicians, respectively) indicated they had patients who experienced CINV 5-7 days after CT. Of the HCPs reporting patients with CINV on Days 5-7, the highest proportions were seen for cisplatin, AC and EC chemotherapy regimens (Table). Table: 2078P
Proportions of respondents with patients experiencing CINV on days 5-7 by chemotherapy regimen
CT Regimen | Pharmacists | Nurses | Physician Prescribers |
Cisplatin | 78% | 71% | 80% |
Epirubicin/cyclophosphamide (EC) | 50% | 43% | 43% |
Anthracycline/cyclophosphamide (AC) | 44% | 45% | 42% |
Carboplatin | 37% | 43% | 48% |
Irinotecan | 41% | 37% | 37% |
Oxaliplatin | 36% | 32% | 28% |
Conclusions
This survey highlights a need for continued assessment of CINV beyond the delayed phase after CT to better understand the incidence and to optimize prevention of CINV for the entire period of risk.
Clinical trial identification
Editorial acknowledgement
Jennifer Vanden Burgt.
Legal entity responsible for the study
Helsinn Healthcare.
Funding
Helsinn Healthcare.
Disclosure
F. Scotté: Financial Interests, Personal, Advisory Board: Helsinn Healthcare, Vifor, MSD, Tesaro; Financial Interests, Personal, Financially compensated role: Roche, Amgen, Pfizer, Leo Pharma, Viatris, Mundi Pharma, Clovis Oncology, BMS, Biogaran, Pierre Fabre Oncology, Arrow, GSK. M.S. Aapro: Financial Interests, Personal, Invited Speaker: Amgen, ViforPharma; Financial Interests, Institutional, Other, Grant to SPCC: BMS, ExactSciences, Pfizer, Novartis, Roche, AstraZeneca; Financial Interests, Institutional, Invited Speaker, Grant to SPCC: Helsinn; Financial Interests, Institutional, Other, grant to SPCC: Mundipharma, Fresenius Kabi, Daiichi Sankyo; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Member of Board of Directors: European Cancer Organisation, SIOG, UICC; Financial Interests, Institutional, Member of Board of Directors: SPCC, ALL CAN; Non-Financial Interests, Advisory Role, Confidentiality agreement: Various companies; Non-Financial Interests, Leadership Role: European Cancer Organisation, SPCC, SIOG; Non-Financial Interests, Member: MASCC, SBOC, ASCO; Other, SAB member: European School of Oncology. Y. Takeuchi: Financial Interests, Personal, Full or part-time Employment: Intage Healthcare Inc. All other authors have declared no conflicts of interest.
Resources from the same session
2076P - Topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy: An exploratory subgroup analysis of the D-ToRCH phase III trial
Presenter: Akhil Santhosh
Session: Poster session 06
2077P - A randomized, placebo-controlled trial assessing the efficacy and safety of the combination of superoxide dismutase, alpha lipoic acid, vitamin B12, B1, B2, B6, E, Mg, Zn and a fatty acid for 6 months in the management of chemotherapy induced neuropathic pain
Presenter: Triantafylos Didangelos
Session: Poster session 06
2079P - Naloxegol for the treatment of opioid-induced constipation in patients with cancer pain: A pooled analysis of real-world studies (NALOPOOL)
Presenter: Maria del Carmen Beato Zambrano
Session: Poster session 06
2080P - Incidence and risks of intravenous chemotherapy-induced neutropenia (ICIN) in oncology: A multicenter retrospective cohort study on real-life data
Presenter: Olivia Rohr
Session: Poster session 06
2081P - The therapeutic effect of anti-inflammatory tripeptide cream on hand-foot syndrome related to anticancer drugs: A prospective, randomized, placebo-controlled pilot trial
Presenter: Yaewon Yang
Session: Poster session 06
2082P - TASMAN: An international survey on the knowledge, aTtitudes and clinical pAtternsS of use of Medical Cannabis for caNcer care
Presenter: Marco Filetti
Session: Poster session 06
2083P - Association between VTE location and risk of recurrent, bleeding and death in the international prospective TESEO SEOM cancer cohort
Presenter: Rocío Martín Lozano
Session: Poster session 06
2084P - Cardiovascular (CV) mortality among metastatic cancer patients: A retrospective cohort study
Presenter: Irbaz Riaz
Session: Poster session 06
2085P - Buprenorphine use and cancer outcomes
Presenter: Nosayaba Osazuwa-Peters
Session: Poster session 06